157 related articles for article (PubMed ID: 31953165)
1. Analysis of vismodegib resistance in D473G and W535L mutants of SMO receptor and design of novel drug derivatives using molecular dynamics simulations.
Liao S; Floyd C; Verratti N; Leung L; Wu C
Life Sci; 2020 Mar; 244():117302. PubMed ID: 31953165
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
Sinha N; Chowdhury S; Sarkar RR
Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795
[TBL] [Abstract][Full Text] [Related]
3. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F
Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392
[TBL] [Abstract][Full Text] [Related]
4. Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.
Shimizu Y; Ishii T; Ogawa K; Sasaki S; Matsui H; Nakayama M
Eur J Pharmacol; 2015 Oct; 764():220-227. PubMed ID: 26048307
[TBL] [Abstract][Full Text] [Related]
5. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
[TBL] [Abstract][Full Text] [Related]
6. Vismodegib resistance in basal cell carcinoma: not a smooth fit.
Ridky TW; Cotsarelis G
Cancer Cell; 2015 Mar; 27(3):315-6. PubMed ID: 25759014
[TBL] [Abstract][Full Text] [Related]
7. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
8. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
Zhang H; Sun Z; Liu Z; Song C
Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
[TBL] [Abstract][Full Text] [Related]
9. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.
Sharpe HJ; Pau G; Dijkgraaf GJ; Basset-Seguin N; Modrusan Z; Januario T; Tsui V; Durham AB; Dlugosz AA; Haverty PM; Bourgon R; Tang JY; Sarin KY; Dirix L; Fisher DC; Rudin CM; Sofen H; Migden MR; Yauch RL; de Sauvage FJ
Cancer Cell; 2015 Mar; 27(3):327-41. PubMed ID: 25759019
[TBL] [Abstract][Full Text] [Related]
10. USP28 and USP25 are downregulated by Vismodegib in vitro and in colorectal cancer cell lines.
Wang H; Meng Q; Ding Y; Xiong M; Zhu M; Yang Y; Su H; Gu L; Xu Y; Shi L; Zhou H; Zhang N
FEBS J; 2021 Feb; 288(4):1325-1342. PubMed ID: 32578360
[TBL] [Abstract][Full Text] [Related]
11. Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
Atwood SX; Sarin KY; Whitson RJ; Li JR; Kim G; Rezaee M; Ally MS; Kim J; Yao C; Chang AL; Oro AE; Tang JY
Cancer Cell; 2015 Mar; 27(3):342-53. PubMed ID: 25759020
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the Allosteric Effect of Antagonist Vismodegib on Smoothened Receptor Deactivation Using Metadynamics Simulation.
An X; Bai Q; Bai F; Shi D; Liu H; Yao X
Front Chem; 2019; 7():406. PubMed ID: 31214579
[TBL] [Abstract][Full Text] [Related]
13. Deciphering structural stability and binding mechanisms of potential antagonists with smoothened protein.
Sinha N; Chowdhury S; Sarkar RR
J Biomol Struct Dyn; 2018 Aug; 36(11):2917-2937. PubMed ID: 28849750
[TBL] [Abstract][Full Text] [Related]
14. Computational analysis of Amsacrine resistance in human topoisomerase II alpha mutants (R487K and E571K) using homology modeling, docking and all-atom molecular dynamics simulation in explicit solvent.
Sader S; Wu C
J Mol Graph Model; 2017 Mar; 72():209-219. PubMed ID: 28110185
[TBL] [Abstract][Full Text] [Related]
15. Molecular modeling study on resistance of WT/D473H SMO to antagonists LDE-225 and LEQ-506.
Tu J; Li JJ; Song LT; Zhai HL; Wang J; Zhang XY
Pharmacol Res; 2018 Mar; 129():491-499. PubMed ID: 29175550
[TBL] [Abstract][Full Text] [Related]
16. Structural optimization on a virtual screening hit of smoothened receptor.
Song S; Jiang J; Zhao L; Wang Q; Lu W; Zheng C; Zhang J; Ma H; Tian S; Zheng J; Luo L; Li Y; Yang ZJ; Zhang X
Eur J Med Chem; 2019 Jun; 172():1-15. PubMed ID: 30939349
[TBL] [Abstract][Full Text] [Related]
17. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.
Brinkhuizen T; Reinders MG; van Geel M; Hendriksen AJ; Paulussen AD; Winnepenninckx VJ; Keymeulen KB; Soetekouw PM; van Steensel MA; Mosterd K
J Am Acad Dermatol; 2014 Nov; 71(5):1005-8. PubMed ID: 25199678
[No Abstract] [Full Text] [Related]
19. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
20. Triazoles bind the C-terminal domain of SMO: Illustration by docking and molecular dynamics simulations the binding between SMO and triazoles.
Liu M; Liang G; Zheng H; Zheng N; Ge H; Liu W
Life Sci; 2019 Jan; 217():222-228. PubMed ID: 30543826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]